Related references
Note: Only part of the references are listed.Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy
Valentina Rossi et al.
BREAST (2014)
Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
Denise A. Yardley et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node-Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX
Otto Metzger-Filho et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tumour heterogeneity in the clinic
Philippe L. Bedard et al.
NATURE (2013)
The Implications of Clonal Genome Evolution for Cancer Medicine
Samuel Aparicio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
Debu Tripathy et al.
ONCOLOGIST (2013)
Testing for Discordance at Metastatic Relapse: Does It Matter?
Stephen Chia
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer
Eitan Amir et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Heterogeneity in breast cancer
Kornelia Polyak
JOURNAL OF CLINICAL INVESTIGATION (2011)
Survival differences among women with de novo stage IV and relapsed breast cancer
S. Dawood et al.
ANNALS OF ONCOLOGY (2010)
Metastatic Behavior of Breast Cancer Subtypes
Hagen Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
Sohrab P. Shah et al.
NATURE (2009)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Survival of metastatic breast carcinoma patients over a 20-year period - A retrospective analysis based on individual patient data from six consecutive studies
A Gennari et al.
CANCER (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Breast carcinoma survival in Europe and the United States -: A population-based study
M Sant et al.
CANCER (2004)
Revision of the American Joint Committee on Cancer staging system for breast cancer
SE Singletary et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Herceptin((R)) alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials
J Baselga
ONCOLOGY (2001)
Share Paper
